NEW ORLEANS -- The newer atypical antipsychotic drugs may not always outperform the old ones in managing schizophrenia, investigators said here.
MedPage Today Action Points
- Note that these investigators suggest that in schizophrenic patients with a low risk for extrapyramidal side effects, typical antipsychotics may work as well, if the optimal dose for an individual is achieved.
- These presentations were made at an industry-sponsored satellite symposium.
NEW ORLEANS, Nov. 22 -- The newer atypical antipsychotic drugs may not always outperform the old ones in managing schizophrenia, investigators said here.
That's what the results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggested, said Rajiv Tandon, M.D., of the University of Florida in Tallahassee.
Dr. Tandon discussed the CATIE trial and its results at a symposium held in conjunction with the U.S. Psychiatric & Mental Health Congress here. The symposium was sponsored by Janssen pharmaceuticals of Titusville, N.J.
In CATIE, nearly 1,500 patients with schizophrenia (ages 18 to 65) were recruited at 57 sites in the U.S. Participants were randomly assigned to Zyprexa (olanzapine) at 7.5 to 30 mg per day, Triavil (perphenazine) at 8 to 32 mg per day, Seroquel (quetiapine) at 200 to 800 mg per day, Risperdal (risperidone) at 1.5 to 6 mg per day, or Geodon (ziprasidone) at 40 to 160 mg per day.
